GlassScriptPhysician profile
Mohammad Shoari
NPI 1740483395
$5,954.95
in general payments reported to CMS, 2019-2025
22 companies · $3,739 in 2025
The $3,739 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $107 · 2021: $13.70 · 2022: $752 · 2023: $374 · 2024: $476 · 2025: $3,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,415 · Food and Beverage: $2,155 · Education: $18.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,414.85 |
| Food and Beverage | $2,155.48 |
| Education | $18.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,016.92 | 2022-2025 | Percept PC Brainsense |
| Neuropace, INC. | $1,546.45 | 2025 | |
| Livanova USA, INC. | $1,065.23 | 2019-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $334.85 | 2021-2024 | Qulipta, Botox, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $215.77 | 2019-2020 | |
| Argenx US, INC. | $120.93 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Acorda Therapeutics, INC | $110.39 | 2019 | |
| Ucb, INC. | $86.45 | 2025 | Rystiggo |
| Acadia Pharmaceuticals INC | $59.65 | 2020-2023 | Nuplazid |
| Biohaven Pharmaceutical Holding Company LTD. | $58.66 | 2022 | |
| Boston Scientific Corporation | $57.55 | 2019 | |
| Mdd US Operations, LLC | $48.26 | 2020 | |
| Celgene Corporation | $33.14 | 2023 | Zeposia |
| Amneal Pharmaceuticals LLC | $30.70 | 2022-2023 | Rytary |
| Lilly USA, LLC | $30.39 | 2022-2023 | Emgality, Reyvow |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $29.49 | 2023 | Xeomin |
| Genentech USA, INC. | $26.65 | 2022 | |
| Jazz Pharmaceuticals INC. | $23.30 | 2024 | |
| Supernus Pharmaceuticals, INC. | $17.93 | 2019 | |
| Greenwich Biosciences, INC. | $17.14 | 2019 | |
| Lundbeck LLC | $13.14 | 2023 | Vyepti |
| Allergan, INC. | $11.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Shoari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.